Show simple item record

dc.contributor.authorHata, J
dc.contributor.authorArima, H
dc.contributor.authorZoungas, S
dc.contributor.authorFulcher, G
dc.contributor.authorPollock, C
dc.contributor.authorAdams, M
dc.contributor.authorWatson, J
dc.contributor.authorJoshi, R
dc.contributor.authorKengne, AP
dc.contributor.authorNinomiya, T
dc.contributor.authorAnderson, C
dc.contributor.authorWoodward, M
dc.contributor.authorPatel, A
dc.contributor.authorMancia, G
dc.contributor.authorPoulter, N
dc.contributor.authorMcMahon, S
dc.contributor.authorChalmers, J
dc.contributor.authorNeal, B
dc.date.accessioned2019-12-04T00:58:37Z
dc.date.available2019-12-04T00:58:37Z
dc.date.issued2013-02-04
dc.identifier.citationHata J, Arima H, Zoungas S, et al. Effects of the Endpoint Adjudication Process on the Results of a Randomised Controlled Trial: The ADVANCE Trial. Boutron I, ed. PLoS ONE. 2013;8(2):e55807. doi:10.1371/journal.pone.0055807en_AU
dc.identifier.urihttps://hdl.handle.net/2123/21464
dc.description.abstractBackground: Endpoint adjudication committees (EPAC) are widely used in clinical trials. The aim of the present analysis is to assess the effects of the endpoint adjudication process on the main findings of the ADVANCE trial (Trial registration: ClinicalTrials.gov NCT00145925). Methods and Findings: The ADVANCE trial was a multicentre, 2×2 factorial randomised controlled trial of blood pressure lowering and intensive blood glucose control in 11140 patients with type 2 diabetes. Primary outcomes were major macrovascular (nonfatal myocardial infarction, nonfatal stroke and cardiovascular death) and microvascular (new or worsening nephropathy and retinopathy) events. Suspected primary outcomes were initially reported by the investigators at the 215 sites with subsequent adjudication by the EPAC. The EPAC also adjudicated upon potential events identified directly by ongoing screening of all reported events. Over a median follow-up of 5 years, the site investigators reported one or more primary outcomes among 2443 participants. After adjudication these events were confirmed for 2077 (85%) with 48 further events added through the EPAC-led database screening process. The estimated relative risk reductions (95% confidence intervals) in the primary outcome for the blood pressure lowering comparison were 8% (−1 to 15%) based on the investigator-reported events and 9% (0 to 17%) based on the EPAC-based events (P for homogeneity = 0.70). The corresponding findings for the glucose comparison were 8% (1 to 15%) and 10% (2% to 18%) (P for homogeneity = 0.60). The effect estimates were also highly comparable when studied separately for macrovascular events and microvascular events for both comparisons (all P for homogeneity>0.6). Conclusions: The endpoint adjudication process had no discernible impact on the main findings in ADVANCE. These data highlight the need for careful consideration of the likely impact of an EPAC on the findings and conclusions of clinical trials prior to their establishment.en_AU
dc.language.isoen_AUen_AU
dc.publisherPLoS ONEen_AU
dc.relationNHMRC GNT0571281, NHMRC GNT1003111en_AU
dc.titleEffects of the Endpoint Adjudication Process on the Results of a Randomised Controlled Trial: The ADVANCE Trialen_AU
dc.typeArticleen_AU
dc.identifier.doi10.1371/journal.pone.0055807
dc.type.pubtypePublisher versionen_AU


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record